Skip To Content



Clinical Connection


Thought leadership on the clinical impact on workers' compensation and auto no-fault.

3Q 2023 Brand-Generic Pipeline

October 12, 2023 · Clinical Team

The following list represents a summary of new medications approved by the U.S. Food and Drug Administration (FDA) and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. Off-label use for the treatment of conditions outside of FDA-approved indications may not be supported by medical treatment guidelines or Optum Workers’ Compensation and Auto No-Fault. Please note this list is not all-inclusive.

New medications

Medication description Strength(s) and dosage form(s) Class/Indication
ZavzpretTM (zavegepant) 10 mg nasal spray Calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults
BrixadiTM (buprenorphine) extended-release injection for subcutaneous use Weekly use: 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL, and 32 mg/0.64 mL single-dose prefilled syringes Monthly use: 64 mg/0.18 mL, 96 mg/0.27 mL, and 128 mg/0.36 mL single-dose prefilled syringes Opioid antagonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine

First-time generics or brand alternatives

Generic name Brand-name Strength(s) and dosage form(s) Class/Indication
Tiotropium Spiriva® HandiHaler® 18 mcg capsule for use with HandiHaler Bronchodilator indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and for reducing symptoms of COPD


If you have any questions, please contact our Clinical Services team at 1-877-275-7674 ext. 8612.


Disclaimer: The information contained herein is provided as-is for informational purposes only and does not constitute medical advice or formal utilization review. This document should not be used in place of a licensed medical practitioner’s independent medical examination, opinion or practice. Optum makes no warranties or representations as to the accuracy or effectiveness of any medical treatment guidelines, formularies or FDA-approved indications that are published after the date of this document.

Clinical Connection